Account
Inquiry
QSC Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The qsc tirzepatide molecule exhibits greater affinity for GIP receptors while maintaining significant GLP-1 receptor activity. This unique dual mechanism has shown promising results in preclinical studies for metabolic regulation. The compound mimics natural GIP action at GIP receptors while providing extended GLP-1 activity.
Our qsc tirzepatide is supplied as white lyophilized powder with purity exceeding 99%, suitable for various research applications. The product is carefully synthesized and purified under strict quality control measures to ensure batch-to-batch consistency.
Key features of our qsc tirzepatide include: high biological activity, excellent stability when properly stored, and reliable performance in research settings. The compound is provided in sealed vials to maintain integrity during transport and storage.
Important Note: This product is intended for research purposes only. Not for human or veterinary use. Researchers should handle all materials with appropriate safety precautions in laboratory settings.
